- A systematic review and meta-analysis suggest that silent corticotroph adenomas (SCAs) have a 25%-31% recurrence rate after primary treatment, similar to other nonfunctioning pituitary adenoma (NFPA) subtypes.
Why this matters
- Studies comparing the recurrence rates of SCAs with other NFPA subtypes have shown conflicting results.
- The recurrence rate was 5.96 (95% CI, 4.30-7.84) per 100 person-years.
- 5.41 (95% CI, 3.28-7.96) per 100 person-years after surgery alone and
- 4.88 (95% CI, 0.67-11.54) per 100 person-years after surgery plus radiotherapy.
- In studies with mean follow-up
- In studies with mean follow-up ≥5 years, the recurrence rate was 31%.
- SCAs and other NFPA subtypes had similar recurrence rates (recurrence rate ratio [RRR], 1.44; P=.13).
- RRR, 1.17 (P=.43) in patients treated with surgery alone.
- 14 studies with 297 patients were included in the meta-analysis.
- Funding: None.
- Moderate risk for bias in included studies.